Gulf Pharmaceutical Industries PSC (JULPHAR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Gulf Pharmaceutical Industries PSC (JULPHAR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10150
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:UAE
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Gulf Pharmaceutical Industries PSC (Julphar) is a pharmaceutical company that manufactures and distributes medicines in the Middle East and North Africa (MENA) region. The company’s product portfolio consists of antibiotics, antiseptics, wound care and biotechnology, women care, adult primary care, pediatric primary care, cardiopulmonary care, gastro care and pain management and consumer care products. The company has manufacturing facilities in Ethiopia, Bangladesh and Saudi Arabia. Julphar has offices in Asia, Middle East and Africa and is headquartered in Digdaga, Ras Al Khaimah, the UAE.

Gulf Pharmaceutical Industries PSC (JULPHAR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Gulf Pharmaceutical Industries PSC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Gulf Pharmaceutical Industries PSC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Gulf Pharmaceutical Industries PSC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Gulf Pharmaceutical Industries PSC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Gulf Pharmaceutical Industries PSC, Medical Devices Deals, 2012 to YTD 2018 10
Gulf Pharmaceutical Industries PSC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Gulf Pharmaceutical Industries PSC, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
EMD Millipore Enters Into Co-Marketing Agreement With Julphar Diabetes For Recombinant Human Insulin 12
MSD Enters Into Distribution Agreement With Julphar 13
Licensing Agreements 14
Gulf Pharmaceutical Industries (Julphar) Enters into Licensing Agreement with Merck 14
Gulf Pharma Enters into Licensing Agreement with MSD 15
BMG Pharma Enters Into Licensing Agreement With Julphar For Ginoxil 16
Acquisition 17
Julphar Acquires 77.5% Stake in RAK Pharma for USD9.5 Million 17
Gulf Pharmaceutical Industries PSC – Key Competitors 18
Gulf Pharmaceutical Industries PSC – Key Employees 19
Gulf Pharmaceutical Industries PSC – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Joint Venture 21
Recent Developments 22
Financial Announcements 22
Aug 19, 2018: Julphar Posts Solid First Half Results 22
May 17, 2018: Julphar Announces Q1 Results 23
Mar 06, 2018: Julphar Targets Double-Digit Growth in 2018 24
Nov 19, 2017: Julphar announces Q3 2017 results 25
Corporate Communications 26
Aug 27, 2017: Julphar’s Board of Directors appoints Jerome Carle as General Manager 26
Jan 29, 2017: Julphar CEO leaves the company after 8 years of service 27
Jan 09, 2017: Julphar appoints new CFO 28
Product News 29
Dec 18, 2017: Julphar Marks Entry into New Sector at First Men’s Health Congress 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Gulf Pharmaceutical Industries PSC, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Gulf Pharmaceutical Industries PSC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Gulf Pharmaceutical Industries PSC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Gulf Pharmaceutical Industries PSC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Gulf Pharmaceutical Industries PSC, Deals By Therapy Area, 2012 to YTD 2018 8
Gulf Pharmaceutical Industries PSC, Medical Devices Deals, 2012 to YTD 2018 10
Gulf Pharmaceutical Industries PSC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
EMD Millipore Enters Into Co-Marketing Agreement With Julphar Diabetes For Recombinant Human Insulin 12
MSD Enters Into Distribution Agreement With Julphar 13
Gulf Pharmaceutical Industries (Julphar) Enters into Licensing Agreement with Merck 14
Gulf Pharma Enters into Licensing Agreement with MSD 15
BMG Pharma Enters Into Licensing Agreement With Julphar For Ginoxil 16
Julphar Acquires 77.5% Stake in RAK Pharma for USD9.5 Million 17
Gulf Pharmaceutical Industries PSC, Key Competitors 18
Gulf Pharmaceutical Industries PSC, Key Employees 19
Gulf Pharmaceutical Industries PSC, Subsidiaries 20
Gulf Pharmaceutical Industries PSC, Joint Venture 21

List of Figures
Gulf Pharmaceutical Industries PSC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Gulf Pharmaceutical Industries PSC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Gulf Pharmaceutical Industries PSC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Gulf Pharmaceutical Industries PSC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Gulf Pharmaceutical Industries PSC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Gulf Pharmaceutical Industries PSC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Gulf Pharmaceutical Industries PSC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Gulf Pharmaceutical Industries PSC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Gulf Pharmaceutical Industries PSC, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Gulf Pharmaceutical Industries PSC (JULPHAR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Nitori Holdings Co Ltd:企業の戦略・SWOT・財務分析
    Nitori Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Nitori Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Porcelanosa Grupo AIE:企業の戦略・SWOT・財務情報
    Porcelanosa Grupo AIE - Strategy, SWOT and Corporate Finance Report Summary Porcelanosa Grupo AIE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Wacoal Holdings Corp (3591):企業の財務・戦略的SWOT分析
    Wacoal Holdings Corp (3591) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • University of Texas Health Science Center at Houston-製薬・医療分野:企業M&A・提携分析
    Summary University of Texas Health Science Center at Houston (UTHealth), a subsidiary of University of Texas System is an educational institution that provides research, education and patient care services. The university operates with schools of biomedical informatics, biomedical sciences, dentistr …
  • OncoSec Medical Inc (ONCS):企業の財務・戦略的SWOT分析
    Summary OncoSec Medical Inc (OncoSec) is a biotechnology company. The company offers services to stimulate body’s immune system and attack cancer. It’s lead candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor t …
  • CTI BioPharma Corp (CTIC):製薬・医療:M&Aディール及び事業提携情報
    Summary CTI BioPharma Corp (CTI BioPharma) is a biopharmaceutical company, which acquires, develops, and commercializes targeted therapies for a range of blood-related cancers. The company’s lead product, Pixuvri (pixantrone) is an aza-anthracenedione used for the treatment of multiply relapsed or r …
  • Alliance MMA, Inc. (AMMA):企業の財務・戦略的SWOT分析
    Alliance MMA, Inc. (AMMA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • ARK Diagnostics Inc:企業の製品パイプライン分析
    Summary ARK Diagnostics Inc (ARK Diagnostics) is a developer, manufacturer and commercializer of in vitro diagnostic immunoassay products. The company's products include protease inhibitors, levetiracetam assay, topiramate assay, non-nucleoside reverse transcriptase inhibitors, gabapentin assay, lam …
  • Royal KPN N.V.:企業の戦略・SWOT・財務情報
    Royal KPN N.V. - Strategy, SWOT and Corporate Finance Report Summary Royal KPN N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Bimini Capital Management, Inc.:企業の戦略・SWOT・財務情報
    Bimini Capital Management, Inc. - Strategy, SWOT and Corporate Finance Report Summary Bimini Capital Management, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Westgold Resources Limited (WGX):企業の財務・戦略的SWOT分析
    Westgold Resources Limited (WGX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Fortive Corporation:企業の戦略・SWOT・財務情報
    Fortive Corporation - Strategy, SWOT and Corporate Finance Report Summary Fortive Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Sonoco Products Co (SON):企業の財務・戦略的SWOT分析
    Sonoco Products Co (SON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Origin Energy Ltd (ORG):石油・ガス:M&Aディール及び事業提携情報
    Summary Origin Energy Ltd (Origin Energy) is an integrated energy company. It generates, supplies and distributes electricity; explores and develops natural gas reserves; and produces and sells gas. The company generates electricity from natural-gas fired, coal-fired, wind, solar, pumped water stora …
  • JinkoSolar Holding Co Ltd (JKS):電力:M&Aディール及び事業提携情報
    Summary JinkoSolar Holding Co Ltd (JinkoSolar) is a manufacturer of solar products. The company is involved in manufacturing and marketing of solar power products such as silicon ingots, silicon wafers, solar modules, solar PV cells, and monocrystalline and multicrystalline photovoltaic (PV) panels. …
  • Bureau Veritas SA (BVI):企業の財務・戦略的SWOT分析
    Bureau Veritas SA (BVI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Quanterix Corp (QTRX):医療機器:M&Aディール及び事業提携情報
    Summary Quanterix Corp (Quanterix) is a life sciences company that develops and markets ultra-sensitive digital immunoassay platform that improves precision health for life sciences research and diagnostics. The company develops platform based on its proprietary digital single molecule array, Simoa …
  • Infogroup Inc:企業の戦略・SWOT・財務情報
    Infogroup Inc - Strategy, SWOT and Corporate Finance Report Summary Infogroup Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • International SOS Pte Ltd:企業の戦略的SWOT分析
    International SOS Pte Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Formosa Petrochemical Corp (6505):企業の財務・戦略的SWOT分析
    Formosa Petrochemical Corp (6505) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆